Investigational Drug Information for Elvucitabine
✉ Email this page to a colleague
What is the development status for investigational drug Elvucitabine?
Elvucitabine is an investigational drug.
There have been 6 clinical trials for Elvucitabine.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2008.
The most common disease conditions in clinical trials are HIV Infections, Infections, and Immunologic Deficiency Syndromes. The leading clinical trial sponsors are Achillion Pharmaceuticals, Alexion Pharmaceuticals, and Thomas Jefferson University.
Summary for Elvucitabine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 949 |
| WIPO Patent Applications | 577 |
| Japanese Patent Applications | 235 |
| Clinical Trial Progress | Phase 2 (2008-05-01) |
| Vendors | 27 |
Recent Clinical Trials for Elvucitabine
| Title | Sponsor | Phase |
|---|---|---|
| An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment | Bellos, Nicholaos C., M.D. | Phase 2 |
| An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment | Center for the Prevention and Treatment of Infections | Phase 2 |
| An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment | Central Texas Primary Care Research Network | Phase 2 |
Clinical Trial Summary for Elvucitabine
Top disease conditions for Elvucitabine
Top clinical trial sponsors for Elvucitabine
US Patents for Elvucitabine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
